A case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab

Australasian Journal of DermatologyEarly View CLINICAL LETTER A case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab Yang Ying MD, Yang Ying MD orcid.org/0000-0002-6907-0707 Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, ChinaSearch for more papers by this authorLiu Yu-Hua MMed, Liu Yu-Hua MMed Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, ChinaSearch for more papers by this authorWu Xiao-Yan MMed, Wu Xiao-Yan MMed Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, ChinaSearch for more papers by this authorHou Su-Chun PhD, Corresponding Author Hou Su-Chun PhD [email protected] Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China Correspondence Hou Su-Chun, Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, 1, Haiyuan 1st Road, Futian District, Shenzhen, Guangdong, China. Email: [email protected]Search for more papers by this author Yang Ying MD, Yang Ying MD orcid.org/0000-0002-6907-0707 Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, ChinaSearch for more papers by this authorLiu Yu-Hua MMed, Liu Yu-Hua MMed Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, ChinaSearch for more papers by this authorWu Xiao-Yan MMed, Wu Xiao-Yan MMed Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, ChinaSearch for more papers by this authorHou Su-Chun PhD, Corresponding Author Hou Su-Chun PhD [email protected] Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China Correspondence Hou Su-Chun, Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, 1, Haiyuan 1st Road, Futian District, Shenzhen, Guangdong, China. Email: [email protected]Search for more papers by this author First published: 18 May 2023 https://doi.org/10.1111/ajd.14076Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Wang D, Chong VC, Chong WS, et al. A review on pityriasis rubra pilaris. Am J Clin Dermatol. 2018; 19(3): 377– 90. https://doi.org/10.1007/s40257-017-0338-1 2Eastham AB. Pityriasis Rubra Pilaris. JAMA Dermatol. 2019; 155(3): 404. https://doi.org/10.1001/jamadermatol.2018.5030 3Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: a review of the literature. J Am Acad Dermatol. 2018; 79(2): 353– 9. https://doi.org/10.1016/j.jaad.2018.03.036 4Tegtmeyer K, Zhao J, Maloney NJ, Atassi G, Beestrum M, Lio PA. Off-label studies on tofacitinib in dermatology: a review. J Dermatolog Treat. 2021; 32(4): 399– 409. https://doi.org/10.1080/09546634.2019.1673877 5Roenneberg S, Biedermann T. Pityriasis rubra pilaris: algorithms for diagnosis and treatment. J Eur Acad Dermatol Venereol. 2018; 32(6): 889– 98. https://doi.org/10.1111/jdv.14761 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation